Amneal Pharmaceuticals, Inc.·4

May 8, 7:23 PM ET

BURR ROBERT L 4

4 · Amneal Pharmaceuticals, Inc. · Filed May 8, 2018

Insider Transaction Report

Form 4
Period: 2018-05-04
Transactions
  • Award

    Stock Option

    2018-05-04+10,00010,000 total
    Exercise: $27.97Exp: 2021-05-11Class A Common Stock (10,000 underlying)
  • Award

    Class A Common Stock

    2018-05-04+6,0576,057 total(indirect: By IRA)
  • Award

    Stock Option

    2018-05-07+24,97724,977 total
    Exercise: $15.01Exp: 2028-05-07Class A Common Stock (24,977 underlying)
  • Award

    Stock Option

    2018-05-04+10,57510,575 total
    Exercise: $30.33Exp: 2026-05-17Class A Common Stock (10,575 underlying)
  • Award

    Stock Option

    2018-05-04+12,00012,000 total
    Exercise: $17.99Exp: 2023-05-15Class A Common Stock (12,000 underlying)
  • Award

    Stock Option

    2018-05-04+10,00010,000 total
    Exercise: $20.90Exp: 2022-05-23Class A Common Stock (10,000 underlying)
  • Award

    Class A Common Stock

    2018-05-04+60,47560,475 total
  • Award

    Stock Option

    2018-05-04+7,3007,300 total
    Exercise: $44.85Exp: 2025-05-12Class A Common Stock (7,300 underlying)
  • Award

    Stock Option

    2018-05-04+10,00010,000 total
    Exercise: $20.30Exp: 2020-05-26Class A Common Stock (10,000 underlying)
  • Award

    Stock Option

    2018-05-04+30,00030,000 total
    Exercise: $6.55Exp: 2019-05-20Class A Common Stock (30,000 underlying)
  • Award

    Restricted Stock Units

    2018-05-07+6,1076,107 total
    Class A Common Stock (6,107 underlying)
  • Award

    Stock Option

    2018-05-04+11,50011,500 total
    Exercise: $25.24Exp: 2024-05-14Class A Common Stock (11,500 underlying)
  • Award

    Stock Option

    2018-05-04+10,57510,575 total
    Exercise: $16.40Exp: 2027-05-16Class A Common Stock (10,575 underlying)
Footnotes (7)
  • [F1]Received in exchange for 60,475 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA").
  • [F2]Received in exchange for 6,057 shares of Impax common stock pursuant to the BCA.
  • [F3]The option is vested and currently exercisable.
  • [F4]Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock.
  • [F5]The option vests in four equal annual installments beginning on May 07, 2019.
  • [F6]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
  • [F7]The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION